Mutual of America Capital Management LLC Reduces Stake in Charles River Laboratories Intl. Inc (CRL)

Mutual of America Capital Management LLC trimmed its position in Charles River Laboratories Intl. Inc (NYSE:CRL) by 2.7% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 37,811 shares of the medical research company’s stock after selling 1,057 shares during the quarter. Mutual of America Capital Management LLC owned 0.08% of Charles River Laboratories Intl. worth $4,138,000 at the end of the most recent quarter.

Other institutional investors have also recently added to or reduced their stakes in the company. Ameritas Investment Partners Inc. raised its holdings in shares of Charles River Laboratories Intl. by 2.1% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 14,256 shares of the medical research company’s stock valued at $1,442,000 after buying an additional 291 shares during the period. Public Employees Retirement System of Ohio raised its holdings in shares of Charles River Laboratories Intl. by 1.5% during the 2nd quarter. Public Employees Retirement System of Ohio now owns 22,383 shares of the medical research company’s stock valued at $2,264,000 after buying an additional 330 shares during the period. Ladenburg Thalmann Financial Services Inc. raised its holdings in shares of Charles River Laboratories Intl. by 69.0% during the 3rd quarter. Ladenburg Thalmann Financial Services Inc. now owns 1,342 shares of the medical research company’s stock valued at $145,000 after buying an additional 548 shares during the period. Cardinal Capital Management raised its holdings in shares of Charles River Laboratories Intl. by 7.0% during the 3rd quarter. Cardinal Capital Management now owns 8,447 shares of the medical research company’s stock valued at $912,000 after buying an additional 549 shares during the period. Finally, Norris Perne & French LLP MI raised its holdings in shares of Charles River Laboratories Intl. by 0.6% during the 3rd quarter. Norris Perne & French LLP MI now owns 98,882 shares of the medical research company’s stock valued at $10,681,000 after buying an additional 577 shares during the period. Institutional investors own 97.13% of the company’s stock.

Charles River Laboratories Intl. Inc (CRL) opened at $110.31 on Thursday. The company has a market capitalization of $5,106.20, a P/E ratio of 43.43, a PEG ratio of 1.60 and a beta of 0.74. The company has a debt-to-equity ratio of 1.06, a current ratio of 1.78 and a quick ratio of 1.62. Charles River Laboratories Intl. Inc has a 12-month low of $86.25 and a 12-month high of $119.05.

Charles River Laboratories Intl. (NYSE:CRL) last issued its earnings results on Tuesday, February 13th. The medical research company reported $1.40 EPS for the quarter, topping the consensus estimate of $1.26 by $0.14. Charles River Laboratories Intl. had a return on equity of 26.14% and a net margin of 6.64%. The company had revenue of $478.50 million during the quarter, compared to analyst estimates of $475.02 million. During the same quarter last year, the firm earned $1.21 EPS. The business’s revenue was up 2.5% on a year-over-year basis. research analysts expect that Charles River Laboratories Intl. Inc will post 5.52 earnings per share for the current year.

A number of brokerages have weighed in on CRL. SunTrust Banks upgraded Charles River Laboratories Intl. from a “hold” rating to a “buy” rating and raised their price objective for the company from $107.66 to $125.00 in a research note on Wednesday. Credit Suisse Group restated a “hold” rating and set a $108.00 price objective on shares of Charles River Laboratories Intl. in a research note on Thursday. Royal Bank of Canada set a $116.00 price objective on Charles River Laboratories Intl. and gave the company a “hold” rating in a research note on Tuesday. TheStreet lowered Charles River Laboratories Intl. from an “a-” rating to a “c+” rating in a research note on Tuesday. Finally, JPMorgan Chase & Co. raised their price objective on Charles River Laboratories Intl. from $110.00 to $120.00 and gave the company an “overweight” rating in a research note on Wednesday. Seven investment analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the stock. Charles River Laboratories Intl. presently has a consensus rating of “Buy” and an average price target of $114.85.

In other Charles River Laboratories Intl. news, insider David Ross Smith sold 5,486 shares of Charles River Laboratories Intl. stock in a transaction on Tuesday, January 2nd. The stock was sold at an average price of $109.53, for a total transaction of $600,881.58. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, Director Online Communications Bdirect sold 131,000 shares of Charles River Laboratories Intl. stock in a transaction on Thursday, January 18th. The shares were sold at an average price of $0.29, for a total value of $37,990.00. Insiders have sold a total of 195,673 shares of company stock valued at $2,644,046 in the last 90 days. Insiders own 2.20% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “Mutual of America Capital Management LLC Reduces Stake in Charles River Laboratories Intl. Inc (CRL)” was reported by Week Herald and is the property of of Week Herald. If you are reading this story on another site, it was illegally copied and reposted in violation of US and international copyright & trademark laws. The correct version of this story can be accessed at https://weekherald.com/2018/02/15/mutual-of-america-capital-management-llc-trims-position-in-charles-river-laboratories-intl-inc-crl.html.

About Charles River Laboratories Intl.

Charles River Laboratories International, Inc is an early-stage contract research company. The Company is engaged in laboratory animal medicine and science (research model technologies) and develop a portfolio of discovery and safety assessment services, both good laboratory practice (GLP) and non-GLP, which supports its clients from target identification through non-clinical development.

Institutional Ownership by Quarter for Charles River Laboratories Intl. (NYSE:CRL)

Receive News & Ratings for Charles River Laboratories Intl. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories Intl. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply